COLLEGE OF MEDICINE
20/20 GeneSystems Inc.
9430 Key West Ave., Suite 100, Rockville, MD 20850
240/453-6343, Cell 301/379-2020
Jonathan Cohen, President & CEO, Jcohen@2020gene.com
www.2020gene.com/intro_frame.htm
Enzymax LLC
870 Corporate Drive, Suite 201, Lexington, KY 40503
859/219-8452
www.enzymax.net
Manufactures proteins and enzymes for biomedical research, and offers custom protein purification and custom DNA constructions using advanced biotechnologies. Based on the research of Zhigang Wang, toxicology.
Nano-Mite Technologies LLC
A169 ASTeCC Building, University of Kentucky, Lexington, KY 40506-0286
859/218-6564
www.nano-mite.com
Nano-Mite, based on the research of Patrick G. Sullivan, with UK’s Spinal Cord & Brain Injury Research Center (SCoBIRC) and the Department of Anatomy & Neurobiology, is focused on controlling obesity—in both humans and pets—using nanotechnology. Nano-Mite has developed, and is currently testing, a nano-scale medical device that serves as mitochondrial uncouplers to increase metabolism and result in weight loss.
OsteoRegeneron
859/323-5049
John Williams, jpwill2@pop.uky.edu
OsteoRegeneron is built around three patents obtained for a novel bone chemokine that stimulates osteoblast differentiation. This product will represent the first non-hormonal anabolic agent to increase bone density.
Quanteon LLC
105 Parker Lane, Nicholasville, KY 40356
General ordering: Casie Clements, casie@quanteon.cc, 859/229-5118
Technical Contact: Pete Huetti, pete@quanteon.cc, 859/396-8882
www.quanteon.cc
Develops microsensor technologies to measure neurochemicals, including dopamine, norepinephrine, serotonin, nitric oxide, and glutamate. Microsensor development and fabrication, Windows-based software for data recording and analysis, instrumentation development, and microelectronic interfaces. Based on the research of Greg Gerhardt, medicine.
Stallion Therapeutics Inc.
741 S. Limestone, Lexington, KY 40536
859/425-1043
Ed Hall, edhall@uky.edu
Stallion Therapeutics Inc is a Lexington based start-up pharmaceutical company interested in developing neuroprotective and neurorestorative compounds for traumatic brain injury, spinal cord injury and other acute neurological disorders. The founder of Stallion is Dr. Edward D. Hall, Director of the University of Kentucky Spinal Cord & Brain Injury Research Center (SCoBIRC) and SCoBIRC Endowed Professor of Anatomy & Neurobiology, Neurology and Neurosurgery. Stallion's near term strategy is to develop its programs by pursuing funding through the NIH's STTR/SBIR programs. A pending STTR grant proposal involves testing the efficacy of certain compounds developed in collaboration with NeurOp Inc. (www.neuropinc.com) in models of traumatic brain injury. Stallion will commence its own medicinal chemistry efforts in 2008.